GERON CORP(GERN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
GERN Stock Analysis & AI Quality Score
AI stock analysis and institutional research for GERON CORP (GERN), a Healthcare sector company. GERN is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), GERON CORP reports quarterly revenue of $51.8M, net income of $-3.6M, free cash flow of $-62.9M. Top institutional holders of GERN by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., BlackRock,, Soleus Capital Management, L.P., based on the most recent SEC filings. GERN trades on the Nasdaq exchange and files with the SEC under CIK 886744. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GERN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for GERON CORP directly from SEC EDGAR.
Revenue
Q1 2026
$51.8M
Net Income
Q1 2026
$-3.6M
Free Cash Flow
Q1 2026
$-62.9M
D/E Ratio
Q1 2026
0.52
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
Net Income
+52.2% YoYOperating Income
+60.5% YoYEPS (Diluted)
+51.9% YoYTotal Assets
-3.9% YoYTotal Debt
+0.9% YoYOp. Cash Flow
+49.2% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $237.0K -60.2% | $596.0K -57.2% | $1.4M +450.6% | $253.0K |
| Net Income | $-83.5M +52.2% | $-174.6M +5.2% | $-184.1M -29.8% | $-141.9M -22.2% | $-116.1M -53.6% | $-75.6M |
| Operating Income | $-68.6M +60.5% | $-173.7M +10.4% | $-193.9M -40.0% | $-138.6M -21.5% | $-114.0M -48.2% | $-76.9M |
| EPS (Diluted) | $-0.13 +51.9% | $-0.27 +15.6% | $-0.32 +13.5% | $-0.37 -5.7% | $-0.35 -25.0% | $-0.28 |
| Total Assets | $570.5M -3.9% | $593.8M +50.7% | $394.1M +106.8% | $190.6M -15.7% | $226.0M -16.5% | $270.7M |
| Total Debt | $119.5M +0.9% | $118.5M -8.0% | $128.8M +78.7% | $72.1M +44.7% | $49.8M +107.3% | $24.0M |
| Operating Cash Flow | $-111.0M +49.2% | $-218.6M -30.3% | $-167.7M -31.7% | $-127.4M -33.3% | $-95.6M -43.4% | $-66.7M |
Get alerted when GERN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for GERON CORP including:
Top Institutional Holders of GERN
RA CAPITAL MANAGEMENT, L.P.
$95.0M63,771,366 shBlackRock, Inc.
$70.5M47,319,779 shSoleus Capital Management, L.P.
$61.8M41,508,659 shDeep Track Capital, LP
$47.3M31,720,278 shSTATE STREET CORP
$45.4M30,497,183 shVANGUARD CAPITAL MANAGEMENT LLC
$39.7M26,669,029 shCITADEL ADVISORS LLC
$32.1M21,576,569 shPoint72 Asset Management, L.P.
$30.5M20,457,134 shClearbridge Investments, LLC
$29.2M19,620,320 shEversept Partners, LP
$28.1M18,834,883 sh
| Fund | Value | Shares |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $95.0M | 63,771,366 |
| BlackRock, Inc. | $70.5M | 47,319,779 |
| Soleus Capital Management, L.P. | $61.8M | 41,508,659 |
| Deep Track Capital, LP | $47.3M | 31,720,278 |
| STATE STREET CORP | $45.4M | 30,497,183 |
| VANGUARD CAPITAL MANAGEMENT LLC | $39.7M | 26,669,029 |
| CITADEL ADVISORS LLC | $32.1M | 21,576,569 |
| Point72 Asset Management, L.P. | $30.5M | 20,457,134 |
| Clearbridge Investments, LLC | $29.2M | 19,620,320 |
| Eversept Partners, LP | $28.1M | 18,834,883 |
More Healthcare Companies
View all Healthcare →Put GERN on your watchlist
Track score changes the day GERON CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is GERN a good stock to buy?
13F Pro's AI-powered analysis of GERON CORP (GERN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GERN are available on the GERN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own GERN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GERN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of GERON CORP's investment landscape.